In 2010 the PIP breast implant scandal erupted after the French medical watchdog AFSSAPS discovered that they were being made with a gel that had not been approved for medical use. By the time that Jean-Claude Mas, founder of PIP, and four other executives were convicted in late 2013 for their involvement in the affair, the media had already highlighted the company's many failings, including the way it fiddled safety inspections to hide the poor nature of its products. And last October Mediapart revealed how AFSSAPS itself – now known as the Agence nationale pour la sécurité du médicament (ANSM) – had been slow to react to the problem.
You are a subscriber
Login
If you are not already a subscriber,
subscribe here
Choose a subscription offer and create your account to read all content on Mediapart
Create your account